BECLOMETASONE EXTRA-FINE / FORMOTEROL (Fostair pMDI®)

Clinical Indication

Asthma & COPD

Comments

The LLR asthma guidelines have been updated (May 2024). Fostair pMDI is no longer recommended as an option. Please review all patients to see if they can be changed to a formulary choice dry powder inhaler device in the first instance. Where an MDI device is required please review to Luforbec in line with guidance.

The LLR COPD guidelines have been updated (June 2026) and ICS/LABA combinations are no longer routinely recommended as a treatment option. No NEW initiations. For patients established on this therapy, treatment should be reviewed on a case-by-case basis, taking into account clinical stability and patient preference. Ongoing prescribing should be in line with the updated COPD guidelines.

Date of classification

May 2026